Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes
| Autor: | Mika Suematsu, Nobutaka Nakamura, Takanori Matsui, Kuniyoshi Kaseda, Sho-ichi Yamagishi |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Glycation End Products
Advanced medicine.medical_specialty Dipeptidyl Peptidase 4 Receptor for Advanced Glycation End Products Gene Expression Diabetic angiopathy medicine.disease_cause RAGE (receptor) Glycation Alzheimer Disease Diabetes mellitus Internal medicine Neoplasms Genetics medicine Adenosine Deaminase Inhibitors Humans Molecular Biology Genetics (clinical) Dipeptidyl peptidase-4 business.industry Articles Aptamers Nucleotide medicine.disease Molecular medicine Oxidative Stress Endocrinology Diabetes Mellitus Type 1 Diabetes Mellitus Type 2 Cardiovascular Diseases Molecular Medicine Osteoporosis Alzheimer's disease business Oxidative stress Diabetic Angiopathies |
| Zdroj: | Molecular medicine (Cambridge, Mass.). 21 |
| ISSN: | 1528-3658 |
| Popis: | A nonenzymatic reaction between reducing sugars and amino groups of proteins, lipids and nucleic acids contributes to the aging of macromolecules and subsequently alters their structural integrity and function. This process has been known to progress at an accelerated rate under hyperglycemic and/or oxidative stress conditions. Over a course of days to weeks, early glycation products undergo further reactions such as rearrangements and dehydration to become irreversibly cross-linked, fluorescent and senescent macroprotein derivatives termed advanced glycation end products (AGEs). There is a growing body of evidence indicating that interaction of AGEs with their receptor (RAGE) elicits oxidative stress generation and as a result evokes proliferative, inflammatory, thrombotic and fibrotic reactions in a variety of cells. This evidence supports AGEs’ involvement in diabetes- and aging-associated disorders such as diabetic vascular complications, cancer, Alzheimer’s disease and osteoporosis. Therefore, inhibition of AGE formation could be a novel molecular target for organ protection in diabetes. This report summarizes the pathophysiological role of AGEs in vascular complications in diabetes and discusses the potential clinical utility of measurement of serum levels of AGEs for evaluating organ damage in diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink